The phototherapy treatment market is experiencing steady growth, driven by increasing adoption of advanced technologies and strategies by leading industry players. From 2025 to 2035, the market is expected to expand significantly due to these factors and the presence of major companies in key regions.
Currently valued at \$7.41 billion in 2023, the market is projected to reach \$7.79 billion in 2024 and grow to \$11.5 billion by 2032. This represents a compound annual growth rate of 5.0%. The expanding use of phototherapy in dermatology, neonatology, and mental health is making it an important treatment option in hospitals and specialty clinics worldwide.
Phototherapy uses ultraviolet or visible light to treat various conditions, such as neonatal jaundice, chronic skin diseases like psoriasis and vitiligo, and some mood disorders. It is popular because it is non-invasive, has few side effects, and effectively manages long-term illnesses. For businesses involved in manufacturing equipment, hospitals, and distributors, the market offers strong commercial opportunities.
One of the main drivers behind this growth is the rising prevalence of skin disorders, including eczema, psoriasis, and vitiligo. These conditions have become more common due to genetic, environmental, and lifestyle factors. UVB phototherapy and PUVA therapy are increasingly used as affordable first-line treatments. Atopic dermatitis is also growing among children and adults, sustaining demand for advanced phototherapy devices.
Technological innovation is playing a key role in market development. LED-based devices are becoming popular because they consume less energy, last longer, and deliver precise wavelengths. Advances in narrowband UVB therapy and full-body light units improve patient comfort and treatment success while increasing operational efficiency. Portable and handheld devices now allow home-based treatment, benefiting patients with limited access to clinics.
Awareness about the benefits of phototherapy is also rising. More healthcare providers recommend it due to its effectiveness and safer profile compared to long-term drug use. Public health campaigns and physician endorsements contribute to higher adoption rates globally, including in both developed and developing countries.
Reimbursement policies and insurance coverage are important for market growth. Favorable reimbursement for UV light therapy in psoriasis and phototherapy for neonatal jaundice encourages hospitals and specialty centers to invest in high-quality equipment. This financial support is crucial for expanding the market.
However, competition from alternative treatments like biologics and topical medicines challenges the market. To remain competitive, manufacturers must innovate to enhance precision, safety, and treatment speed. The integration of digital diagnostics and AI monitoring could further improve the value of phototherapy devices in clinical settings.
The market is segmented by treatment type, disease application, device type, treatment modality, end user, and region. Treatments include UVB and UVA therapies, blue and red light therapies. Disease applications cover psoriasis, eczema, acne, vitiligo, neonatal jaundice, and seasonal affective disorder. Devices range from stationary hospital units to portable and wearable systems used in clinics or at home. Key users are hospitals, dermatology clinics, neonatal care units, and wellness centers.
Geographically, North America leads the market due to strong healthcare infrastructure, good reimbursement systems, and early adoption of new technology. Europe follows, driven by high rates of skin diseases and government support for non-invasive treatments. The Asia-Pacific region is rapidly growing, with rising healthcare investment and awareness in countries such as India, China, and Japan. Latin America and the Middle East & Africa regions are also expanding, supported by increased public-private partnerships and local manufacturing efforts.
Related Topics:
